Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema

Abstract This study was performed to investigate the efficacy of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema (DME). This prospective, multicentre, interventional, single-arm, 104-week clinical trial included 48 patients with DME visual impairment. The patients...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yu Cheol Kim, Jae Pil Shin, Kang Yeun Pak, Hyun Woong Kim, Min Sagong, Sang Joon Lee, In Young Chung, Sung Who Park, Ji Eun Lee
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/6509824431054246a144362bb90f6349
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6509824431054246a144362bb90f6349
record_format	dspace
spelling	oai:doaj.org-article:6509824431054246a144362bb90f63492021-12-02T11:57:58ZTwo-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema10.1038/s41598-020-78954-32045-2322https://doaj.org/article/6509824431054246a144362bb90f63492020-12-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-78954-3https://doaj.org/toc/2045-2322Abstract This study was performed to investigate the efficacy of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema (DME). This prospective, multicentre, interventional, single-arm, 104-week clinical trial included 48 patients with DME visual impairment. The patients’ eyes received five consecutive intravitreal injections (2 mg aflibercept) every four weeks with two-week adjustments based on central subfield macular thickness (CSMT) changes. Injections were deferred when CSMT was stable. The number of injections, best-corrected visual acuity (BCVA), CSMT, and diabetic retinopathy severity scale scores were analysed. Compared to baseline, BCVA improved by + 9.1 letters at 52 weeks and was maintained with + 9.4-letter gain at 104 weeks (P < 0.001). Between baseline and 104 weeks, CSMT decreased from 489 to 298 μm (P < 0.001) and eyes with vision ≥ 20/40 increased from 17.4 to 43.5% (P = 0.007). The mean number of injections decreased from 8.5 in year one to 3.9 in year two. The injection interval was extended to ≥ 12 weeks in 56.5% of patients. The treat-and-extend regimen of aflibercept in DME showed 2-year efficacy comparable to that of fixed dosing regimens. The flexible dosing of this regimen reduced the number of injections in year two while maintaining efficacy.Yu Cheol KimJae Pil ShinKang Yeun PakHyun Woong KimMin SagongSang Joon LeeIn Young ChungSung Who ParkJi Eun LeeNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-7 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yu Cheol Kim Jae Pil Shin Kang Yeun Pak Hyun Woong Kim Min Sagong Sang Joon Lee In Young Chung Sung Who Park Ji Eun Lee Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema
description	Abstract This study was performed to investigate the efficacy of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema (DME). This prospective, multicentre, interventional, single-arm, 104-week clinical trial included 48 patients with DME visual impairment. The patients’ eyes received five consecutive intravitreal injections (2 mg aflibercept) every four weeks with two-week adjustments based on central subfield macular thickness (CSMT) changes. Injections were deferred when CSMT was stable. The number of injections, best-corrected visual acuity (BCVA), CSMT, and diabetic retinopathy severity scale scores were analysed. Compared to baseline, BCVA improved by + 9.1 letters at 52 weeks and was maintained with + 9.4-letter gain at 104 weeks (P < 0.001). Between baseline and 104 weeks, CSMT decreased from 489 to 298 μm (P < 0.001) and eyes with vision ≥ 20/40 increased from 17.4 to 43.5% (P = 0.007). The mean number of injections decreased from 8.5 in year one to 3.9 in year two. The injection interval was extended to ≥ 12 weeks in 56.5% of patients. The treat-and-extend regimen of aflibercept in DME showed 2-year efficacy comparable to that of fixed dosing regimens. The flexible dosing of this regimen reduced the number of injections in year two while maintaining efficacy.
format	article
author	Yu Cheol Kim Jae Pil Shin Kang Yeun Pak Hyun Woong Kim Min Sagong Sang Joon Lee In Young Chung Sung Who Park Ji Eun Lee
author_facet	Yu Cheol Kim Jae Pil Shin Kang Yeun Pak Hyun Woong Kim Min Sagong Sang Joon Lee In Young Chung Sung Who Park Ji Eun Lee
author_sort	Yu Cheol Kim
title	Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema
title_short	Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema
title_full	Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema
title_fullStr	Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema
title_full_unstemmed	Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema
title_sort	two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/6509824431054246a144362bb90f6349
work_keys_str_mv	AT yucheolkim twoyearoutcomesofthetreatandextendregimenusingafliberceptfortreatingdiabeticmacularoedema AT jaepilshin twoyearoutcomesofthetreatandextendregimenusingafliberceptfortreatingdiabeticmacularoedema AT kangyeunpak twoyearoutcomesofthetreatandextendregimenusingafliberceptfortreatingdiabeticmacularoedema AT hyunwoongkim twoyearoutcomesofthetreatandextendregimenusingafliberceptfortreatingdiabeticmacularoedema AT minsagong twoyearoutcomesofthetreatandextendregimenusingafliberceptfortreatingdiabeticmacularoedema AT sangjoonlee twoyearoutcomesofthetreatandextendregimenusingafliberceptfortreatingdiabeticmacularoedema AT inyoungchung twoyearoutcomesofthetreatandextendregimenusingafliberceptfortreatingdiabeticmacularoedema AT sungwhopark twoyearoutcomesofthetreatandextendregimenusingafliberceptfortreatingdiabeticmacularoedema AT jieunlee twoyearoutcomesofthetreatandextendregimenusingafliberceptfortreatingdiabeticmacularoedema
_version_	1718394751254790144

Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema

Ejemplares similares